Search

Displaying results 1371 - 1380 of 10000 in total
  1. Drug

    Prasugrel

    go.drugbank.com/drugs/DB06209
    ApprovedInvestigational

    R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. … FDA approved in 2009.

  2. Drug

    Zidovudine

    go.drugbank.com/drugs/DB00495
    ApprovedInvestigational

    Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem] … A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group.

    Mixtures: LAMIVUDINA E ZIDOVUDINA MYLAN, LAMIVUDINA E ZIDOVUDINA MYLANCategories: Antivirals used in combination for the treatment of HIV infections
  3. Drug

    Bimekizumab

    go.drugbank.com/drugs/DB12917
    ApprovedInvestigational

    Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis. … Bimekizumab was also granted FDA approval on October 18, 2023.[L48551]

  4. Drug

    Ospemifene

    go.drugbank.com/drugs/DB04938
    Approved

    FDA approved on February 26, 2013. … Ospemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause

  5. Drug

    Ipratropium

    go.drugbank.com/drugs/DB00332
    ApprovedInvestigational

    ] was approved in 1996. … Ipratropium is a quaternary ammonium derivative of [atropine][A176957] that acts as an anticholinergic agent.

    Mixtures: SALBUTAMOLO E IPRATROPIO BROMURO EG, BERODUAL N METERED DOSE INHALERSynonyms: Ipratropium ion
  6. Drug

    Triamterene

    go.drugbank.com/drugs/DB00384
    Approved

    [A177985] Since it acts on the distal nephron where only a small fraction of sodium ion reabsorption occurs, triamterene is reported to have limited diuretic efficacy. … It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side.

    Mixtures: TRIAMETERENO E HIDROCLOROTIAZIDA CAPSULAS
  7. Drug

    Tositumomab

    go.drugbank.com/drugs/DB00081
    ApprovedWithdrawn

    It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine).

  8. Drug

    Flibanserin

    go.drugbank.com/drugs/DB04908
    ApprovedInvestigational

    in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters. … Flibanserin's mechanism of action is attributed to its high affinity for 5-HTA1 and 5-HTA2 receptors, displaying agonist activity on 5-HTA1 and antagonist on 5-HTA2, resulting in lowering of serotonin

  9. Drug

    Calaspargase pegol

    go.drugbank.com/drugs/DB14730
    ApprovedInvestigational

    Calaspargase pegol, by _Shire_ pharmaceuticals, was approved by the FDA on December 20, 2018 for acute lymphoblastic anemia (ALL) [L4890]. … Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Zanidatamab

    go.drugbank.com/drugs/DB15471
    ApprovedInvestigational

    Zanidatamab is a bispecific antibody that binds two non-overlapping sites of HER2 (ERBB2). … [A264718] In November 2024, the FDA granted an accelerated approval for zanidatamab for use in previously treated unresectable or metastatic HER2-positive biliary tract cancers.[L51908,L51903]

    Synonyms: SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINEPROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODY, BIPARATOPIC (TARGETING TWO DIFFERENT NON-OVERLAPP